Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS5626 in Active Noninfectious Uveitis (Phase II)
CTR20255083Phase 2Active
- Sponsor
- Accro Bioscience
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FXS5626 in uveitis, sponsored by Accro Bioscience. Started Dec 2025; status: active.
02
Drugs
FXS5626
03
Conditions
uveitis
Beyond the preview
Go deeper on CTR20255083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255083.